2-Propan-2-yl-4-pyrrolidin-1-ylpyrimidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Propan-2-yl-4-pyrrolidin-1-ylpyrimidine
• 英文别名: 2-propan-2-yl-4-pyrrolidin-1-ylpyrimidine
• 化学式: C₁₁H₁₇N₃
• 分子量: 191.27
• InChiKey: UDWOYJKBDOBPHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline, LLC

  公开号：US20140288052A1

  公开（公告）日：2014-09-25

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型取代的双环氮杂杂环类sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和障碍，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症和/或潮红，以及需要增强线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗剂组合的组合物。
• Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators
  申请人：GlaxoSmithKline, LLC

  公开号：US20140249147A1

  公开（公告）日：2014-09-04

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的取代双环氮杂杂环类Sirtuin调节化合物及其使用方法。这些Sirtuin调节化合物可用于增加细胞寿命，治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块性疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。同时，还提供了包含Sirtuin调节化合物和另一种治疗剂的组合物。
• Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
  申请人：An2H Discovery Limited

  公开号：US10308617B2

  公开（公告）日：2019-06-04

  The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

  本公开涉及式(I)和式(II)的三唑苯甲酰胺化合物、其药物组合物以及调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶有关的疾病或病症的方法。R1、R2、R3、M1、M2、M3、L1、L2 和 L3 如本文所定义。
• TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
  申请人：An2H Discovery Limited

  公开号：US20180118697A1

  公开（公告）日：2018-05-03

  The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R 1 , R 2 , R 3 , M 1 , M 2 , M 3 , L 1 , L 2 , and L 3 are as defined herein.
• US9957271B2
  申请人：——

  公开号：US9957271B2

  公开（公告）日：2018-05-01